According to the Market Statsville Group (MSG), China Biologic and Biosimilar Market size was valued at USD 72,315.8 million in 2023, which is expected to grow from USD 88,128.3 million in 2024 to USD 137,729.0 million by 2033, at a CAGR of 8.6% during the forecast period (2024 to 2033).
China's biological and biosimilar market is supposed to take off at a drastic rate shortly. The growth in demand is for advanced therapies, and the regulatory environment seems most welcoming. Biologics are complex molecules; monoclonal antibodies and recombinant proteins apply to an increasing number of chronic diseases treatment, including cancer, diabetes, and autoimmune disorders. Another factor is the huge investment that China is investing in biopharmaceutical research and development activities, which will also provide an impetus to the market.
Another reason the biosimilar segment is becoming popular is due to lower prices compared to the original biologics. That makes it more pocket-friendly both for healthcare providers and patients. Domestic corporations, such as Shanghai Fosun Pharmaceutical and Innovent Biologics, are at the forefront of the development of competitive biosimilars. Regulatory reforms, including streamlined approval processes by the NMPA, permitted faster access of such drugs to the market. Against the backdrop of innovation, policy support, and rising health demand, it is expected that the China biologic and biosimilar market will grow considerably.
The China biologic and biosimilar market involves the development, production, and commercialization of biologic drugs and their biosimilars alike. Biologics refer to large-molecule drugs extracted from living organisms like animals and plants to be used against a myriad of diseases. Biosimilars are almost similar copies of their biologics counterparts with equal potency and safety but at low prices. It involves innovation, regulatory aid, and an increased demand for enhanced facilities for medical treatment in China.
One major factor driving the biologics and biosimilar market is the growth in healthcare demand in China, driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and auto-immune disorders. All these conditions require advanced treatments that have mostly better efficacy than the average treatments using small-molecule drugs. Biologics—being structurally complex and of targeted mechanisms of action—yield better therapeutic outcomes in such chronic diseases. For example, monoclonal antibodies will bind more precisely to cancer cells and cause less damage in healthy tissues for cancer treatment.
Other biologics, such as insulin analogs and immune-modulating agents, are vital in the management of diabetes and autoimmune disorders respectively. The need for these advanced therapies is gaining ground with population aging and changes in Chinese lifestyles that raise the incidences of chronic diseases. It's a surge in demand that has consequently compelled pharmaceutical companies to invest more in developing and marketing biologic and biosimilar products, thus compelling general growth of the market.
Production of biologics and biosimilars is very challenging due to the intrinsic complexity of these products by nature; technically advanced technology coupled with specialized expertise is required. Unlike small-molecule drugs, biologics are large complex molecules derived from living cells, requiring sophisticated biotechnological processes. It requires precisely controlled conditions for the manufacture of these products to ensure uniform quality, efficacy, and safety.
Besides, the stability of biologics during the manufacturing process, storage, and distribution is another very important and challenging factor. Added to this is the complexity coming from the stringent regulatory requirements for proving similarity and safety between a biosimilar and its reference biologic. The overall situation sets a high barrier to entry for any new player, as this involves investing in state-of-the-art facilities and highly qualified personnel. This complexity increases production costs and, accordingly, stretches out development timelines, making it rather hard to find a competitive contestant in the biologics and biosimilars market under the realm of small to medium-sized companies or even a new entrant.
The study categorizes the China Biologic and Biosimilar market based on product type, application, end-users, and distribution channels at the regional and regional levels.
Based on the product type, the market is divided into Insulins, Monoclonal Antibodies, Growth Hormones, Erythropoietin, Enzymes, Colony-Stimulating Factors, and Others. Monoclonal antibodies have dominated the Chinese biologic and biosimilar market. High effectiveness in treating different kinds of chronic diseases, notably cancer and autoimmune disorders, powers their dominance. In other words, monoclonal antibodies allow for targeted therapy in that they can attack the diseased cells without interfering with the healthy ones; hence, they can provide better results for the patients and are linked with fewer incidences of after-effects.
The rising cases of cancer in China have, thus, created a correspondingly large market demand for said therapies. Furthermore, both local and international pharmaceutical giants have invested huge sums in research and development, basically ensuring sufficient pipeline products of monoclonal antibodies. The NMPA has also formulated pertinent regulations that will ensure the speeding up of approval and quick access of these biologics to the market. Consequently, broad applicability and strong R&D focus make monoclonal antibodies the biggest piece of this pie in the Chinese biologics and biosimilar market.
With large domestic players such as Shanghai Fosun Pharmaceutical and Innovent Biologics, among others, and global pharmaceutical leaders competing in the China biologic and biosimilar market, the companies invest in R&D and strategic collaborations to boost their pipelines. Rising competition due to growing markets, coupled with support from regulatory bodies, acts as a catalyst for innovation and expansion of market share.
Major players in the China Biologic and Biosimilar market are:
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024Liver Health Supplements Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024